METEDA SRL

Their core work

METEDA SRL is a Rome-based digital health SME that builds software tools and decision support systems at the intersection of nutrition science, metabolic health, and chronic disease management. In practice, they contribute the data-driven and consumer-facing technology layer to research consortia: translating omics-derived biomarkers or clinical screening data into actionable recommendations for patients, families, and primary care providers. Their work spans from personalized meal planning backed by metabolomics to mobile health applications that help people with diabetes and hypertension self-manage their conditions. They consistently operate at the point where scientific evidence meets everyday user behavior, building the digital bridge between laboratory findings and real-world health outcomes.

What they specialise in

How they've shifted over time

In their earliest H2020 work (2018), METEDA was firmly in the personalized nutrition space — metabolomics, biomarkers, food ingredients, and dietary decision support grounded in omics science. By 2021, their focus had moved upstream from food into clinical digital health: the language shifted from metabolomics and personalised meals to diabetes, hypertension, screening, people-centred care, and scaling-up. The underlying thread — using data and digital tools to change individual health behavior — remained consistent, but the application domain broadened from nutrition into chronic disease management in community and primary care settings.

METEDA is moving from niche food-omics applications toward broader digital health platforms for chronic disease prevention, a market with significant scaling potential and strong EU policy alignment around people-centred primary care.

How they like to work

METEDA has participated exclusively as a consortium partner — never as coordinator — across both projects, suggesting they join larger multidisciplinary teams as a specialist technology contributor rather than driving consortia themselves. With 37 unique partners across 13 countries from just two projects, they are embedded in genuinely large, diverse consortia typical of EU Innovation Actions and Research Actions in health and food. This profile suggests they are reliable, capable partners who contribute a defined technical component — likely the software platform or digital tool layer — without requiring overall project leadership.

METEDA has built connections with 37 distinct consortium partners across 13 countries through only two projects — an unusually broad network for such a small portfolio, indicating involvement in large, well-funded EU consortia with wide geographic representation. No repeated partner patterns are visible from the data, suggesting they bring specialist value that complements diverse teams rather than anchoring a recurring collaboration cluster.

What sets them apart

METEDA occupies a specific and commercially relevant niche: they can take scientific outputs — whether omics biomarkers or clinical screening data — and turn them into working software tools that end users actually interact with, including patients, families, and primary care professionals. Few SMEs combine that translation capability with experience in both the food science domain and the chronic disease clinical domain, making them a practical bridge between research-heavy partners and real-world deployment. For a consortium that has good science but needs a credible digital product layer, METEDA fills that gap without requiring them to grow into a coordinator role.

Highlights from their portfolio

• DigiCare4You
  The largest of METEDA's funded projects (€426,694, running to 2026) and their most clinically ambitious — targeting diabetes and hypertension management through an m-health platform deployed in community and primary healthcare settings across multiple countries.
• PREVENTOMICS
  An unusual combination of cutting-edge omics science with consumer product design and business model development, positioning METEDA at the frontier of precision nutrition before it became mainstream.